Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Cue Biopharma is a biotechnology business based in the US. Cue Biopharma shares (CUE) are listed on the NASDAQ and all prices are listed in US Dollars. Cue Biopharma employs 57 staff and has a trailing 12-month revenue of around $11.7 million.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Active traders
| Latest market close | $2.39 |
|---|---|
| 52-week range | $2.18 - $18.42 |
| 50-day moving average | $2.92 |
| 200-day moving average | $4.97 |
| Wall St. target price | $11.67 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.44 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.39 from 2022-10-03
| 1 week (2022-09-28) | 2.39 |
|---|---|
| 1 month (2022-09-02) | -22.65% |
| 3 months (2022-07-05) | -9.81% |
| 6 months (2022-04-04) | -56.47% |
| 1 year (2021-10-05) | -81.36% |
|---|---|
| 2 years (2020-10-05) | -85.34% |
| 3 years (2019-10-04) | 7.72 |
| 5 years (2017-10-01) | N/A |
| Revenue TTM | $11.7 million |
|---|---|
| Gross profit TTM | $-26,405,395 |
| Return on assets TTM | -34.74% |
| Return on equity TTM | -73.63% |
| Profit margin | 0% |
| Book value | $1.69 |
| Market capitalisation | $84.6 million |
TTM: trailing 12 months
We're not expecting Cue Biopharma to pay a dividend over the next 12 months.
Over the last 12 months, Cue Biopharma's shares have ranged in value from as little as $2.18 up to $18.42. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cue Biopharma's is 1.6599. This would suggest that Cue Biopharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Cue Biopharma, Inc. , a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine.
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.